Small-cap stock Lincoln Pharmaceuticals gained nearly 12% in BSE trade on Wednesday i.e. December 4 and touched a record high of ₹843.60. Shares of Lincoln Pharma opened at ₹782.90 compared to its previous close of ₹754.10 and rose 11.9% to hit a historic high of ₹843.60. Lincoln Pharma’s share price has surged more than 30 percent in just three December sessions.
According to the company’s exchange filings, Lincoln Pharma is a debt-free company. By September 2024, the company has achieved an annual net profit of over ₹100 crore and investments of over ₹164 crore, with healthy return ratios.
The company has reported standalone net profit of ₹50.03 crore for the 6 month period ended September 30, 2024, an YoY growth of 7.55% as against ₹46.52 crore for the same period last year. Operating income for H1FY25 stood at ₹308.50 crore, up 5.79% year-on-year (YoY). EBITDA for the period stood at ₹71.50 crore, up 4.76% YoY.
Commenting on the H1FY25 results and performance, Mahendra Patel, MD, Lincoln Pharmaceuticals said, “We are pleased to report continued strong growth across all business segments in H1FY25, while maintaining our debt-free status. Have been. The launch of our new products has strengthened our presence in the domestic and export markets, positioning us for even better performance in the second half.
The company exports to more than 60 countries. It is poised for further global expansion after recently entering the Canadian market and receiving approval from Australia and EU GMP. Apart from this, it is also actively promoting product registration for its Cephalosporin plant at Mehsana. These initiatives are helping the company achieve its revenue target of ₹750 crore for FY26.
lincoln pharma shares
Lincoln Pharma shares touched a record high of ₹843.60 today, on Dec 4. At this price, the stock has gained 69% from its 52-week low of ₹498, which was hit on June 5 this year.
Disclaimer: This information is for informational purposes only and should not be construed as investment advice. It is recommended to consult a financial advisor before making investment decisions.